Evidence map›Paper›PMID 30728442›Full record

ArticleScientific reports2019

The Amazon rain forest plant Uncaria tomentosa (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles.

Alan D Snow, Gerardo M Castillo, Beth P Nguyen, Paula Y Choi, Joel A Cummings, Judy Cam, Qubai Hu, Thomas Lake, Weihong Pan, Abba J Kastin and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 68 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. ComprehensiveCurrent computer-aided drug design · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 2 countries.

Alan D SnowCognitive Clarity Inc., Edmonds, WA, USA. dralansnow@cognitiveclarityinc.com.
Gerardo M CastilloProteoTech Inc., Kirkland, WA, USA.
Beth P NguyenProteoTech Inc., Kirkland, WA, USA.
Paula Y ChoiProteoTech Inc., Kirkland, WA, USA.
Joel A CummingsCognitive Clarity Inc., Edmonds, WA, USA.
Judy CamProteoTech Inc., Kirkland, WA, USA.
Qubai HuProteoTech Inc., Kirkland, WA, USA.
Thomas LakeCognitive Clarity Inc., Edmonds, WA, USA.
Weihong PanBlood-Brain Barrier Laboratory, Pennington Biomedical Research Center at Louisiana State University, Baton Rouge, Louisiana, USA.
Abba J KastinBlood-Brain Barrier Laboratory, Pennington Biomedical Research Center at Louisiana State University, Baton Rouge, Louisiana, USA.
Daniel A KirschnerDepartment of Biology, Boston College, Chestnut Hill, MA, USA.
Steven G WoodDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA.
Edward RockensteinDepartments of Neurosciences and Pathology, University of California- San Diego, La Jolla, CA, USA.
Eliezer MasliahDepartments of Neurosciences and Pathology, University of California- San Diego, La Jolla, CA, USA.
Stephen LorimerDepartment of Chemistry, University of Otago, Dunedin, New Zealand.
Rudolph E TanziGenetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.ORCID 0000-0002-7032-1454
Lesley LarsenDepartment of Chemistry, University of Otago, Dunedin, New Zealand.
ProteoTech (United States) · USPennington Biomedical Research Center · USUniversity of California San Diego · USUniversity of Otago · NZBoston College · USBrigham Young University · USEKOS Corporation · USHarvard University · USTenet Healthcare · USWashington University in St. Louis · US

Funding

VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4M
B-Synuclein as a Treatment for Lewy Body DiseaseR01AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RISSMAN, ROBERT · 2001 to 2021
$5.2M
Neuroimmune responses and therapeutics of alpha-synucleinopathies of the aging populationZIAAG000936 · NIA · NATIONAL INSTITUTE ON AGING · PI COOKSON, MARK · 2017 to 2025
$4.1M
a-synuclein clearance strategies for the treatment of Lewy body disease.R37AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MASLIAH, ELIEZER · 2006 to 2014
$2.7M
Amyloid Inhibiting Agent for Treatment of Alzheimer'sR44AG016551 · NIA · PROTEOTECH, INC. · PI SNOW, ALAN D. · 2001 to 2005
$2.2M
AMYLOID INHIBITING AGENT FOR ALZHEIMERS DISEASER43AG016551 · NIA · PROTEOTECH, INC. · PI CASTILLO, GERARDO M · 1999 to 1999
–
NIA NIH HHS P50 AG005131NIA NIH HHS R01 AG018440NIA NIH HHS R37 AG018440NIA NIH HHS R43 AG016551NIA NIH HHS R44 AG016551
6 · The paper itself

Abstract

Brain aging and Alzheimer's disease both demonstrate the accumulation of beta-amyloid protein containing "plaques" and tau protein containing "tangles" that contribute to accelerated memory loss and cognitive decline. In the present investigation we identified a specific plant extract and its constituents as a potential alternative natural solution for preventing and reducing both brain "plaques and tangles". PTI-00703 cat's claw (Uncaria tomentosa from a specific Peruvian source), a specific and natural plant extract from the Amazon rain forest, was identified as a potent inhibitor and reducer of both beta-amyloid fibrils (the main component of "plaques") and tau protein paired helical filaments/fibrils (the main component of "tangles"). PTI-00703 cat's claw demonstrated both the ability to prevent formation/aggregation and disaggregate preformed Aβ fibrils (1-42 and 1-40) and tau protein tangles/filaments. The disaggregation/dissolution of Aβ fibrils occurred nearly instantly when PTI-00703 cat's claw and Aβ fibrils were mixed together as shown by a variety of methods including Thioflavin T fluorometry, Congo red staining, Thioflavin S fluorescence and electron microscopy. Sophisticated structural elucidation studies identified the major fractions and specific constituents within PTI-00703 cat's claw responsible for both the observed "plaque" and "tangle" inhibitory and reducing activity. Specific proanthocyanidins (i.e. epicatechin dimers and variants thereof) are newly identified polyphenolic components within Uncaria tomentosa that possess both "plaque and tangle" reducing and inhibitory activity. One major identified specific polyphenol within PTI-00703 cat's claw was epicatechin-4β-8-epicatechin (i.e. an epicatechin dimer known as proanthocyanidin B2) that markedly reduced brain plaque load and improved short-term memory in younger and older APP "plaque-producing" (TASD-41) transgenic mice (bearing London and Swedish mutations). Proanthocyanidin B2 was also a potent inhibitor of brain inflammation as shown by reduction in astrocytosis and gliosis in TASD-41 transgenic mice. Blood-brain-barrier studies in Sprague-Dawley rats and CD-1 mice indicated that the major components of PTI-00703 cat's claw crossed the blood-brain-barrier and entered the brain parenchyma within 2 minutes of being in the blood. The discovery of a natural plant extract from the Amazon rain forest plant (i.e. Uncaria tomentosa or cat's claw) as both a potent "plaque and tangle" inhibitor and disaggregator is postulated to represent a potential breakthrough for the natural treatment of both normal brain aging and Alzheimer's disease.

Indexed as

AmyloidAnimalsBrainCat's ClawFemaleMaleMiceMice, TransgenicNeurofibrillary TanglesPlant ExtractsPlaque, AmyloidProanthocyanidinsRatsRats, Sprague-Dawleytau ProteinsAmyloidPlant ExtractsproanthocyanidinProanthocyanidinstau Proteins

Identifiers

PMID30728442
PMCPMC6365538
OpenAlexW2913303823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.